Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors

Metabolic complications related to antiretroviral therapy are rarely investigated among HIV-infected patients in Asian countries. We investigated the prevalence of and factors associated with metabolic syndrome among HIV-infected patients who are ethnic Chinese in the era of highly active antiretroviral therapy (HAART). A cross-sectional survey was performed to collect information on the demographic and clinical characteristics and antiretroviral therapy prescribed in 877 HIV-infected patients at a university hospital in Taiwan from May 2008 to April 2009. The modified Adult Treatment Panel III criteria were used to define metabolic syndrome after adjusting for the waist circumference criteria for Asians. Of the 877 patients, 75.3 were male homosexuals, 80.7 were receiving HAART and 88.7 had CD4 counts epsilon 200 cells/mm(3). Metabolic syndrome was diagnosed in 210 patients (26.2). After adjusting for age, gender, smoking status, family history of diabetes mellitus, cardiovascular disease and hypertension, and baseline CD4 and plasma HIV RNA load, use of protease inhibitors (PIs) was significantly associated with the presence of metabolic syndrome (OR 1.63; 95 CI 1.102.43). In addition, exposure to PI for epsilon 3 years, to HAART for epsilon 6 years and to nucleoside reverse transcriptase inhibitor(s) for epsilon 6 years was significantly associated with the presence of metabolic syndrome with an adjusted OR of 1.96 (95 CI 1.133.42), 1.78 (95 CI 1.033.07), and 1.91 (95 CI 1.113.30), respectively. Approximately one-fourth of HIV-infected Taiwanese patients developed metabolic syndrome in the HAART era. Receipt of HAART and prolonged exposure to PI and nucleoside reverse transcriptase inhibitor(s) were associated with metabolic syndrome